vancomycin has been researched along with Morbid Obesity in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ghasemiyeh, P; Mohammadi-Samani, S; Vazin, A | 1 |
| Chin, SJ; Clarke, HD; Moore, GA; Spangehl, MJ; Young, SW; Zhang, M | 1 |
| Al Asad, M; Khaleeq, G; Mohyuddin, GR; Scratchko, L | 1 |
| Adane, ED; Herald, M; Koura, F | 1 |
| Caffrey, AR; LaPlante, KL; Morrill, HJ; Noh, E | 1 |
| Hanes, SD; Kane, SP | 1 |
| Billet, SE; El-Azhary, R; Gibson, LE; Kortuem, KR | 1 |
| Hewton, C; Jones, TE; Vasileff, H | 1 |
| Allen, SE; Mercier, RC; Pai, MP | 1 |
| Gubbins, PO; Hickerson, SL; Penzak, SR; Rodvold, KA | 1 |
| Bauer, LA; Black, DJ; Lill, JS | 1 |
| Baranger, B; Brinquin, L; Fangio, P; Petitjeans, F; Rouquette-Vincenti, I; Szymczyszyn, P; Villevieille, T | 1 |
2 review(s) available for vancomycin and Morbid Obesity
| Article | Year |
|---|---|
A Brief Review of Pharmacokinetic Assessments of Vancomycin in Special Groups of Patients with Altered Pharmacokinetic Parameters.
Topics: Anti-Bacterial Agents; Area Under Curve; Drug Monitoring; Female; Humans; Kidney; Microbial Sensitivity Tests; Obesity, Morbid; Vancomycin | 2023 |
Unexplained increases in serum vancomycin concentration in a morbidly obese patient.
Topics: Anti-Bacterial Agents; Cross Reactions; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Obesity, Morbid; Pneumonia, Ventilator-Associated; Vancomycin | 2017 |
1 trial(s) available for vancomycin and Morbid Obesity
| Article | Year |
|---|---|
The AAHKS Clinical Research Award: Intraosseous Regional Prophylaxis Provides Higher Tissue Concentrations in High BMI Patients in Total Knee Arthroplasty: A Randomized Trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Arthroplasty, Replacement, Knee; Awards and Prizes; Body Mass Index; Body Weight; Cefazolin; Female; History, 21st Century; Humans; Male; Middle Aged; Obesity; Obesity, Morbid; Orthopedics; Osteoarthritis, Knee; Prospective Studies; Prosthesis-Related Infections; Subcutaneous Fat; Vancomycin | 2018 |
9 other study(ies) available for vancomycin and Morbid Obesity
| Article | Year |
|---|---|
Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Anti-Bacterial Agents; Ceftriaxone; Cellulitis; Chronic Disease; Clindamycin; Erythema; Female; Fluid Therapy; Humans; Hypotension; Lower Extremity; Lymphedema; Multiple Organ Failure; Obesity, Morbid; Vancomycin; Vasoconstrictor Agents | 2013 |
Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Body Weight; Dose-Response Relationship, Drug; Female; Hospitals, Teaching; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Obesity, Morbid; Prospective Studies; Staphylococcal Infections; Staphylococcus aureus; Tissue Distribution; Vancomycin | 2015 |
Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Topics: Aged; Anti-Bacterial Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Obesity; Obesity, Morbid; Pneumonia, Staphylococcal; Retrospective Studies; Vancomycin | 2015 |
A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Anti-Idiotypic; Autoimmunity; Biopsy; Colectomy; Diagnosis, Differential; Diverticulitis, Colonic; Drug Eruptions; Female; Fluorescent Antibody Technique, Direct; Humans; Ileostomy; Immunoglobulin A; Laparoscopy; Male; Middle Aged; Obesity, Morbid; Skin; Skin Diseases, Vesiculobullous; Surgical Wound Infection; Vancomycin | 2008 |
Should monitoring of vancomycin be delayed? A case of likely nephrotoxicity occasioned by morbid obesity and minimal monitoring.
Topics: Anti-Bacterial Agents; Body Weight; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Kidney Diseases; Obesity, Morbid; Vancomycin | 2012 |
Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.
Topics: Anti-Bacterial Agents; Area Under Curve; Chromatography, High Pressure Liquid; Daptomycin; Humans; Infusions, Intravenous; Male; Methicillin Resistance; Middle Aged; Obesity, Morbid; Pseudomonas Infections; Renal Insufficiency; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2006 |
Therapeutic drug monitoring of vancomycin in a morbidly obese patient.
Topics: Anti-Bacterial Agents; Body Weight; Drug Monitoring; Humans; Male; Middle Aged; Obesity, Morbid; Retrospective Studies; Vancomycin | 1998 |
Vancomycin dosing in morbidly obese patients.
Topics: Adult; Body Weight; Female; Half-Life; Humans; Injections, Intravenous; Male; Obesity, Morbid; Vancomycin | 1998 |
[Obesity, diabetes mellitus, and gas gangrene: a major therapeutic challenge].
Topics: Abscess; Amikacin; Anus Diseases; Buttocks; Candidiasis; Ceftazidime; Colostomy; Combined Modality Therapy; Debridement; Diabetes Mellitus, Type 1; Disease Susceptibility; Drug Therapy, Combination; Fasciitis; Female; Gas Gangrene; Humans; Hyperbaric Oxygenation; Hypertension; Metronidazole; Middle Aged; Obesity, Morbid; Postoperative Complications; Shock, Septic; Vancomycin | 2001 |